Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Total Equity

Last Annual Value

75.41M

3-Year CAGR

-9%

5-Year CAGR

91%

10-Year CAGR

10%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Total Equity

SERA · NASDAQ
CompanyTotal Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
75.41M
2.4%-11.5%N/A 
33.21M
-34.5%-31.6%N/A
14.83M
-18.0%-22.8%-5.5%
60.47M
72.1%4.6%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
125.87M
-25.6%-11.1%N/A
130.66M
14.2%-6.2%10.2%
-31.46M
N/AN/AN/A
70.39M
79.9%-5.2%N/A
-218.60M
N/AN/AN/A
10.94M
N/A-27.5%N/A
20.93M
N/AN/A12.3%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245